Clinical Trials to Validate AI-Driven Drug Repurposing 2026
Supports global clinical trials using explainable AI to repurpose approved therapies for unsolved diseases, especially rare conditions, by validating AI-driven hypotheses in early-phase studies.
Funder: Cures Within Reach
Due Dates: June 26, 2026: Letter of Intent (LOI) submission deadline (11:59pm US Eastern Time)
Funding Amounts: Up to $100,000 per project (includes 10% institutional match); additional $5,000–$10,000 for community engagement
Summary: Supports global clinical trials validating AI-driven repurposing of approved therapies for unsolved diseases, with a focus on rare diseases and robust, explainable AI workflows.
Key Information: 2-stage process (LOI then full proposal); applications must be submitted via ProposalCentral.
Description
This opportunity from Cures Within Reach funds investigator-initiated, proof-of-concept, Phase I or Phase IIA clinical trials that aim to validate drug, biologic, or cellular/gene therapy repurposing opportunities identified by artificial intelligence (AI) models for any unsolved disease. The program encourages proposals addressing rare diseases and prefers the use of off-patent therapies. Eligible trials must use AI-generated data as preclinical support, and the overall AI workflow should provide clear, explainable evidence for the repurposing hypothesis. The grant is open to accredited academic and nonprofit research institutions and health systems worldwide. Community engagement with relevant organizations is strongly encouraged, with additional funding available for this purpose.
